Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance…
Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from…
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company…
Alleviates chemotherapy-induced neuropathyCounteracts tumor promoting signals induced by Antibody Drug Conjugate (ADC) payloadsLUND, SWEDEN / ACCESSWIRE / February 12, 2024…
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan…
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which…
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an…
Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara’s Cloudbreak platform for the development of…
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac…
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on…